Galera Therapeutics Board Approves Extreme 1:200 Reverse Stock Split

summarizeSummary

Galera Therapeutics' board has approved a highly aggressive 1:200 reverse stock split, effective July 12, 2026, a move typically signaling severe financial distress and an attempt to maintain exchange listing.

check_boxKey Events · Corporate Governance and Compliance · GRTX

• Extreme Reverse Stock Split Approved

  The board of directors approved a one-for-two hundred (1:200) reverse stock split of the company's common stock.

• Effective Date Set

  The reverse stock split is expected to become effective on July 12, 2026, with shares trading on a split-adjusted basis starting July 13, 2026.

• Fractional Shares Cashed Out

  No fractional shares will be issued; stockholders will receive cash value based on the closing price prior to the effective date.

• Equity Instruments Adjusted

  The reverse split will proportionately reduce shares available under equity plans and adjust the number and exercise price of outstanding stock options and warrants.

auto_awesomeAnalysis · GRTX · Life Sciences

The board's approval of a 1:200 reverse stock split, following prior shareholder approval, is a critical event for Galera Therapeutics. This aggressive ratio, effective July 12, 2026, is typically a last-resort measure for companies facing delisting due to a low share price. Given the company's recent going concern warning and highly dilutive merger agreement with Obsidian Therapeutics, this move underscores severe financial distress and an urgent need to boost the per-share price, likely to meet exchange listing requirements. While it may temporarily increase the nominal share price, reverse splits often lead to further price erosion and significant shareholder value destruction.